{"schema_version":"secwatch.filing_event.v1","accession":"0000875045-25-000035","form_type":"8-K","ticker":"BIIB","cik":"0000875045","company_name":"BIOGEN INC.","filed_at":"2025-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.540191+00:00","generated_at":"2026-05-17T22:37:33.581380+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Biogen Q2 revenue $2.6B (+7% YoY), GAAP EPS $4.33, raises FY2025 guidance","bullets":["Q2 2025 revenue $2.6B (+7% YoY); GAAP EPS $4.33 (+8%); Non-GAAP EPS $5.47 (+4%).","Raised FY2025 Non-GAAP EPS guidance to $15.50-$16.00 (from $14.50-$15.50); revenue now expected ~flat vs 2024.","LEQEMBI U.S. in-market sales ~$63M (+20% sequential); global ~$160M incl. $35M one-time China shipment.","SKYCLARYS global rev. ~$130M; U.S. ~$78M (+13% seq.); ZURZUVAE $46M (+68% seq.).","Pipeline: salanersen advancing to registrational stage in SMA; felzartamab Phase 3 initiated in rare kidney diseases."],"urls":{"canonical":"https://secwatch.observer/filing/0000875045-25-000035","json":"https://secwatch.observer/filing/0000875045-25-000035.json","markdown":"https://secwatch.observer/filing/0000875045-25-000035.md","text":"https://secwatch.observer/filing/0000875045-25-000035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875045/000087504525000035/0000875045-25-000035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875045/000087504525000035/biib-20250731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T22:37:33.581380+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}